Reardon, D. A., Zalutsky, M. R., Akabani, G., Coleman, R. E., Friedman, A. H., McLendon, R. E., … Bigner, D. D. (2006). Radioimmunotherapy of patients with malignant brain tumors: patient-specific dosing of I-131-labeled anti-tenacin antibody to achieve 44 Gy boost dose to resection cavity margins. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 33, S194–S194.

Reardon, D. A., M. R. Zalutsky, G. Akabani, R. E. Coleman, A. H. Friedman, R. E. McLendon, H. S. Friedman, J. E. Herndon, J. Kirkpatrick, and D. D. Bigner. “Radioimmunotherapy of patients with malignant brain tumors: patient-specific dosing of I-131-labeled anti-tenacin antibody to achieve 44 Gy boost dose to resection cavity margins.” EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 33 (September 1, 2006): S194–S194.

Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, McLendon RE, et al. Radioimmunotherapy of patients with malignant brain tumors: patient-specific dosing of I-131-labeled anti-tenacin antibody to achieve 44 Gy boost dose to resection cavity margins. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2006 Sep 1;33:S194–S194.

Reardon, D. A., et al. “Radioimmunotherapy of patients with malignant brain tumors: patient-specific dosing of I-131-labeled anti-tenacin antibody to achieve 44 Gy boost dose to resection cavity margins.” EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol. 33, SPRINGER, Sept. 2006, pp. S194–S194.

Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, McLendon RE, Friedman HS, Herndon JE, Kirkpatrick J, Bigner DD. Radioimmunotherapy of patients with malignant brain tumors: patient-specific dosing of I-131-labeled anti-tenacin antibody to achieve 44 Gy boost dose to resection cavity margins. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER; 2006 Sep 1;33:S194–S194.